# Johnson & Johnson: insider transactions

SEC CIK 200406. Roles and transactions as reported on Form 4. Latest Form 4 filed 2023-08-25.

## Roles

| Company | Role | Transactions | First | Latest |
| --- | --- | ---: | --- | --- |
| [Kenvue Inc.](/companies/kvue.md) | 10% owner | 1 | 2023-08-23 | 2023-08-23 |
| [Inspire Medical Systems, Inc.](/companies/insp.md) | 10% owner | 4 | 2018-05-07 | 2018-05-07 |
| [Minerva Neurosciences, Inc.](/companies/nerv.md) | 10% owner | 3 | 2015-03-13 | 2017-08-29 |
| [Protagonist Therapeutics, Inc](/companies/ptgx.md) | 10% owner | 5 | 2016-08-16 | 2016-08-16 |

## Transactions: 13

Every transaction reported, newest first. Codes P and S are open-market purchases and sales. Reported price is as stated on the form.

| Date | Company | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | ---: | ---: | ---: | --- |
| 2023-08-23 | [Kenvue Inc.](/companies/kvue.md) | Other (J) | 1,533,830,450 | not reported | not reported | [Form 4](/filings/0001628280-23-030660.md) |
| 2018-05-07 | [Inspire Medical Systems, Inc.](/companies/insp.md) | Conversion (C), derivative | 248,631 | $0.00 | $0 | [Form 4](/filings/0000904454-18-000335.md) |
| 2018-05-07 | [Inspire Medical Systems, Inc.](/companies/insp.md) | Conversion (C), derivative | 1,145,038 | $0.00 | $0 | [Form 4](/filings/0000904454-18-000335.md) |
| 2018-05-07 | [Inspire Medical Systems, Inc.](/companies/insp.md) | Conversion (C) | 37,388 | not reported | not reported | [Form 4](/filings/0000904454-18-000335.md) |
| 2018-05-07 | [Inspire Medical Systems, Inc.](/companies/insp.md) | Conversion (C) | 197,863 | not reported | not reported | [Form 4](/filings/0000904454-18-000335.md) |
| 2017-08-29 | [Minerva Neurosciences, Inc.](/companies/nerv.md) | Other (J) | 3,892,256 | $0.0001 | $389.23 | [Form 4](/filings/0000904454-17-000612.md) |
| 2016-08-16 | [Protagonist Therapeutics, Inc](/companies/ptgx.md) | Conversion (C), derivative | 13,054,830 | $0.00 | $0 | [Form 4](/filings/0000904454-16-001373.md) |
| 2016-08-16 | [Protagonist Therapeutics, Inc](/companies/ptgx.md) | Conversion (C), derivative | 14,000,000 | $0.00 | $0 | [Form 4](/filings/0000904454-16-001373.md) |
| 2016-08-16 | [Protagonist Therapeutics, Inc](/companies/ptgx.md) | Purchase (P) | 583,333 | $12.00 | $7.0m | [Form 4](/filings/0000904454-16-001373.md) |
| 2016-08-16 | [Protagonist Therapeutics, Inc](/companies/ptgx.md) | Conversion (C) | 900,333 | not reported | not reported | [Form 4](/filings/0000904454-16-001373.md) |
| 2016-08-16 | [Protagonist Therapeutics, Inc](/companies/ptgx.md) | Conversion (C) | 965,517 | not reported | not reported | [Form 4](/filings/0000904454-16-001373.md) |
| 2015-03-13 | [Minerva Neurosciences, Inc.](/companies/nerv.md) | Purchase (P), derivative | 607,903 | $0.125 | $76.0k | [Form 4](/filings/0001144204-15-016825.md) |
| 2015-03-13 | [Minerva Neurosciences, Inc.](/companies/nerv.md) | Purchase (P) | 607,903 | $4.81 | $2.9m | [Form 4](/filings/0001144204-15-016825.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 1, 2026, 23:07 ET. No prices; not investment advice.